IP AND COMMERCIALISATION OF LAB282 RESULTS

 
Expert in Residence, Dr Thomas Hanke and Dr John Davis

Expert in Residence, Dr Thomas Hanke and Dr John Davis

WHO WILL OWN IP ARISING FROM FUNDED PROJECTS?

Arising IP will be treated according to Oxford University statutes.


WHAT HAPPENS TO PRE-EXISTING IP THAT IS RELEVANT TO THE APPLICATION FOR FUNDING?

Applicants should work with OUI to identify their relevant background intellectual property controlled by Oxford that would form part of a package of IP to be licensed to a spinout based on results of a LAB282-funded project. It is expected that, subject to any 3rd party rights, this IP will be included in any such package.


HOW WILL THE DOWNSTREAM RESULTS BE COMMERCIALISED?

LAB282 has been established to fuel the creation of new spinout companies from the University of Oxford, and spinout formation will be the preferred route to commercialise the outputs from funded projects. Spinouts based on the results of LAB282 awards will be established based on an equity and IP licence framework agreed by the partners. For more information, please contact Oxford University Innovation.


HOW DO THE DIFFERENT PARTNERS BENEFIT FROM DOWNSTREAM COMMERCIALISATION?

The University of Oxford benefits from founding equity in resulting spinouts, and from a share of revenues generated under the licence of IP to the spinout, as set out in the University IP statutes and regulations.

Oxford University Innovation benefits from a share of revenues generated under the licence of IP to the spinout, and from a share of proceeds from the sale of the University's founding equity, as set out in University IP statutes and regulations.

Oxford Sciences Innovation benefits from founding equity in new companies, conversion of LAB282 awards into equity and additional equity should it choose to invest in a new spinout.

Evotec benefits from founding equity in new spinouts based on LAB282 results, and will provide its services “at-cost”.


HOW WILL ACADEMIC APPLICANTS BENEFIT IN THE EVENT THAT IP ARISING FROM FUNDED PROJECTS IS COMMERCIALISED?

Where a new spinout company is formed based on LAB282 results, academics will – as is currently the case for Oxford spinouts – benefit from founding equity and/or a share of revenues generated under the IP licence.


WHAT HAPPENS IF AT THE END OF A PROJECT THE LAB282 PARTNERS DO NOT WISH TO FORM A NEW COMPANY TO DEVELOP THE RESULTS?

The researchers will be free to work with OUI to establish alternative routes to commercialise LAB282 results.